Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAROUT
NCT06639074Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- Nov 2024
- Primary completion
- Apr 2029
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Mayo Clinic. Primary endpoint: Recurrence-free survival up to 8 years. Started Nov 2024; status: recruiting.
02
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT06639074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06639074.